Matthias Papo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthias Papo has a total of 248 co-authors. Here are the top co-authors by number of shared publications:
- Julien Haroche
Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, CIMI INSERM-UMRS 1135, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
7 shared publications Zahir Amoura
Internal Medicine Department 2 Institut E3M, French Reference Centre for Histiocytosis, Pitié‐Salpȇtrière Hospital, CIMI INSERM‐UMRS 1135, Sorbonne University, Assistance Publique‐Hôpitaux de Paris Paris France
7 shared publications- Francesco Pegoraro
Department of Hematology and Oncology, Meyer Children’s Hospital IRCCS, Florence, Italy
6 shared publications Julien Haroche
Assistance Publique-Hôpitaux de Paris (APHP), Groupe Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Paris, France
5 shared publicationsFleur Cohen‐Aubart
Internal Medicine Department 2 Institut E3M, French Reference Centre for Histiocytosis, Pitié‐Salpȇtrière Hospital, CIMI INSERM‐UMRS 1135, Sorbonne University, Assistance Publique‐Hôpitaux de Paris Paris France
4 shared publications- Jean-François Emile
Paris-Saclay University, Versailles SQY University, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Wiley in HemaSphere
- Vol. 10 (10) , e70499
MEK inhibition achieves robust and durable responses in Erdheim–Chester disease
Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete. We analyzed outcomes of patients with ECD treated with MEKi monotherapy across eight countries and assessed the dynamics and predictors of response, treatment retention, and the safety profile of MEKi. We included 170 patients and were able to evaluate response in 159 (94%) of them. Objective responses were observed in 112 patients (70%), disease stabilization in 35 (22%), and disease progression in 12 (8%). Response rates were independent of treatment lines and underlying molecular alterations. The median time to best response was 14 months, with an estimated 2‐year probability of response of 61% (95% CI 51%–67%). In multivariable analysis, dyslipidemia (odds ratio [OR] 0.359, 95% CI 0.171–0.745) and neurodegeneration (OR 0.354, 95% CI 0.144–0.864) were associated with a lower probability of response to MEKi, while cutaneous and gastrointestinal involvement with a higher probability. After a median follow‐up of 27 months (interquartile range [IQR] 12–57), the treatment retention rate was 76%, with most discontinuations attributable to toxicity. Adverse events were reported in 106 patients (62%) and were severe in 39 patients (23%). The estimated 2‐year event‐free survival was 65% (95% CI 57%–72%), and the estimated 2‐year overall survival was 80% (95% CI 72%–86%). MEKi monotherapy provides robust and durable clinical efficacy in patients with ECD, with high response rates and favorable long‐term outcomes, despite a substantial burden of toxicity.
- 6 October 2026
- Published by Wiley in HemaSphere
- Vol. 10 (10) , e70499
Open AccessMEK inhibition achieves robust and durable responses in Erdheim–Chester disease
Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete. We analyzed outcomes of patients with ECD treated with MEKi monotherapy across eight countries and assessed the dynamics and predictors of response, treatment retention, and the safety profile of MEKi. We included 170 patients and were able to evaluate response in 159 (94%) of them. Objective responses were observed in 112 patients (70%), disease stabilization in 35 (22%), and disease progression in 12 (8%). Response rates were independent of treatment lines and underlying molecular alterations. The median time to best response was 14 months, with an estimated 2‐year probability of response of 61% (95% CI 51%–67%). In multivariable analysis, dyslipidemia (odds ratio [OR] 0.359, 95% CI 0.171–0.745) and neurodegeneration (OR 0.354, 95% CI 0.144–0.864) were associated with a lower probability of response to MEKi, while cutaneous and gastrointestinal involvement with a higher probability. After a median follow‐up of 27 months (interquartile range [IQR] 12–57), the treatment retention rate was 76%, with most discontinuations attributable to toxicity. Adverse events were reported in 106 patients (62%) and were severe in 39 patients (23%). The estimated 2‐year event‐free survival was 65% (95% CI 57%–72%), and the estimated 2‐year overall survival was 80% (95% CI 72%–86%). MEKi monotherapy provides robust and durable clinical efficacy in patients with ECD, with high response rates and favorable long‐term outcomes, despite a substantial burden of toxicity.
- 18 September 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70260
CBL Variants in Suspected Histiocytic Neoplasms: A Retrospective Study of 11 Cases
- 18 September 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70260
CBL Variants in Suspected Histiocytic Neoplasms: A Retrospective Study of 11 Cases
- Open Access
- 7 September 2026
- Published by Wiley in HemaSphere
- Vol. 10 (9) , e70470
Targeted proteomics reveal histiocytosis‐associated neurodegeneration signatures
Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), yet its underlying biology and reliable biomarkers remain poorly defined. The aim of this study was to (1) gain insight into neuroimmunological mechanisms governing ND and (2) assess the clinical value of established and novel biomarkers for ND‐LCH. We applied targeted proteomics and neurofilament light chain (NFL) assays to cerebrospinal fluid (CSF) and plasma from LCH patients with and without ND, with control cohorts. ND‐LCH exhibited a distinct CSF proteomic profile characterized by increased decoy receptors, including interleukin‐1 receptor type 2 (IL‐1RT2), macrophage activation markers, and cytotoxic and immunoregulatory proteins. CSF IL‐1RT2 showed higher specificity for ND‐LCH than CSF NFL (0.99 [0.99–1.0] vs. 0.88 [0.80–0.96]) and tracked longitudinal disease changes. Plasma analyses revealed a complementary immune signature in which NFL correlated with CSF markers, including IL‐1RT2, and distinguished ND‐LCH from controls. In independent plasma NFL cohorts from France and Japan, elevated levels were confirmed in adults with histiocytosis‐associated ND. These findings define a neuroinflammatory signature of ND‐LCH and identify IL‐1RT2 as a novel candidate biomarker for diagnosis and monitoring.
- 7 September 2026
- Published by Wiley in HemaSphere
- Vol. 10 (9) , e70470
Open AccessTargeted proteomics reveal histiocytosis‐associated neurodegeneration signatures
Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), yet its underlying biology and reliable biomarkers remain poorly defined. The aim of this study was to (1) gain insight into neuroimmunological mechanisms governing ND and (2) assess the clinical value of established and novel biomarkers for ND‐LCH. We applied targeted proteomics and neurofilament light chain (NFL) assays to cerebrospinal fluid (CSF) and plasma from LCH patients with and without ND, with control cohorts. ND‐LCH exhibited a distinct CSF proteomic profile characterized by increased decoy receptors, including interleukin‐1 receptor type 2 (IL‐1RT2), macrophage activation markers, and cytotoxic and immunoregulatory proteins. CSF IL‐1RT2 showed higher specificity for ND‐LCH than CSF NFL (0.99 [0.99–1.0] vs. 0.88 [0.80–0.96]) and tracked longitudinal disease changes. Plasma analyses revealed a complementary immune signature in which NFL correlated with CSF markers, including IL‐1RT2, and distinguished ND‐LCH from controls. In independent plasma NFL cohorts from France and Japan, elevated levels were confirmed in adults with histiocytosis‐associated ND. These findings define a neuroinflammatory signature of ND‐LCH and identify IL‐1RT2 as a novel candidate biomarker for diagnosis and monitoring.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 741-751
Prognostic impact of pericardial effusion in patients with acute myocarditis
Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 741-751
Prognostic impact of pericardial effusion in patients with acute myocarditis
Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.
- Open Access
- 1 August 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70233
Longitudinal Monocyte Subset Dynamics as Biomarker in Adult Histiocytosis: Association With Mutational Status, Kinase Inhibitor Exposure and Relapse Risk
- 1 August 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70233
Open AccessLongitudinal Monocyte Subset Dynamics as Biomarker in Adult Histiocytosis: Association With Mutational Status, Kinase Inhibitor Exposure and Relapse Risk
- Open Access
- 19 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (2) , 755-759
Glomeruloid haemangioma in Erdheim–Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor‐A levels
Glomeruloid haemangiomas and extensive angiomas occurred in a small subset of Erdheim-Chester disease patients, all showing markedly elevated vascular endothelial growth factor-A (VEGF-A) levels despite the absence of POEMS (polyneuropathy, organomegaly, M-spike, and skin disease) syndrome. Molecular analyses demonstrated mitogen-activated protein kinase (MAPK)-activated histiocytes without endothelial mutations, supporting a paracrine VEGF-A-driven angiogenesis mechanism underlying these atypical cutaneous lesions.
- 19 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (2) , 755-759
Open AccessGlomeruloid haemangioma in Erdheim–Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor‐A levels
Glomeruloid haemangiomas and extensive angiomas occurred in a small subset of Erdheim-Chester disease patients, all showing markedly elevated vascular endothelial growth factor-A (VEGF-A) levels despite the absence of POEMS (polyneuropathy, organomegaly, M-spike, and skin disease) syndrome. Molecular analyses demonstrated mitogen-activated protein kinase (MAPK)-activated histiocytes without endothelial mutations, supporting a paracrine VEGF-A-driven angiogenesis mechanism underlying these atypical cutaneous lesions.
- Open Access
Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients
Introduction: Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent venous and/or arterial thrombosis. It is frequently associated with systemic lupus erythematosus, and thrombocytopenia is a common manifestation. This study aimed to compare patients with APS, with and without thrombocytopenia, and to describe management and outcomes of severe thrombocytopenia. Methods: We performed a retrospective single-centre study that included 432 patients with APS. Patients were divided into three groups according to the platelet count nadir: severe thrombocytopenia (< 50 G/L), moderate thrombocytopenia (between 50 and 130 G/L) and no thrombocytopenia (≥ 130 G/L). Results: 142 patients developed thrombocytopenia during follow-up (32.9%): 57 (13%) had severe thrombocytopenia (< 50 G/L) and 85 (19.4%) had moderate thrombocytopenia (50–130 G/L). Patients with thrombocytopenia more frequently experienced thrombotic manifestations, including lower limb deep vein thrombosis (49% vs 37%, p=0.014), coronary thrombosis (15% vs 6.6%, p=0.006) and catastrophic antiphospholipid syndrome (CAPS) (27% vs 2.1%, p<0.001). Thrombocytopenia was more frequently associated with pre-eclampsia (16.8% vs 3.7%, p<0.001) and other APS manifestations, including skin (ulcer 4.9% vs 1.4%, p=0.046, cutaneous necrosis 7% vs 0.7%, p<0.001), cardiovascular (MINOCA 7% vs 0.7%, p<0.001, valvular disease 19.7% vs 9.3%, p=0.002), renal (18.3% vs 3.1%, p<0.001) and pulmonary (5.6% vs 1%, p=0.007) manifestations. Aetiologies of severe thrombocytopenia were mainly immune thrombocytopenia (ITP) and CAPS. In patients with severe thrombocytopenia, treatment followed the approach used for primary ITP, and anticoagulation was generally maintained even in the presence of bleeding episodes. Overall survival was poorer in patients with severe thrombocytopenia (p<0.0001). Conclusion: Our results suggest that thrombocytopenia is associated with a more severe APS phenotype and increased mortality.
Open AccessSevere thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients
Introduction: Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent venous and/or arterial thrombosis. It is frequently associated with systemic lupus erythematosus, and thrombocytopenia is a common manifestation. This study aimed to compare patients with APS, with and without thrombocytopenia, and to describe management and outcomes of severe thrombocytopenia. Methods: We performed a retrospective single-centre study that included 432 patients with APS. Patients were divided into three groups according to the platelet count nadir: severe thrombocytopenia (< 50 G/L), moderate thrombocytopenia (between 50 and 130 G/L) and no thrombocytopenia (≥ 130 G/L). Results: 142 patients developed thrombocytopenia during follow-up (32.9%): 57 (13%) had severe thrombocytopenia (< 50 G/L) and 85 (19.4%) had moderate thrombocytopenia (50–130 G/L). Patients with thrombocytopenia more frequently experienced thrombotic manifestations, including lower limb deep vein thrombosis (49% vs 37%, p=0.014), coronary thrombosis (15% vs 6.6%, p=0.006) and catastrophic antiphospholipid syndrome (CAPS) (27% vs 2.1%, p<0.001). Thrombocytopenia was more frequently associated with pre-eclampsia (16.8% vs 3.7%, p<0.001) and other APS manifestations, including skin (ulcer 4.9% vs 1.4%, p=0.046, cutaneous necrosis 7% vs 0.7%, p<0.001), cardiovascular (MINOCA 7% vs 0.7%, p<0.001, valvular disease 19.7% vs 9.3%, p=0.002), renal (18.3% vs 3.1%, p<0.001) and pulmonary (5.6% vs 1%, p=0.007) manifestations. Aetiologies of severe thrombocytopenia were mainly immune thrombocytopenia (ITP) and CAPS. In patients with severe thrombocytopenia, treatment followed the approach used for primary ITP, and anticoagulation was generally maintained even in the presence of bleeding episodes. Overall survival was poorer in patients with severe thrombocytopenia (p<0.0001). Conclusion: Our results suggest that thrombocytopenia is associated with a more severe APS phenotype and increased mortality.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
La maladie d’Erdheim-Chester au-delà de la voie des MAPKinases : association aux néoplasmes myéloïdes et mutations additionnelles, profil des monocytes et de polarisation lymphocytaire T, interaction avec l’ostéogénèse
La maladie d’Erdheim-Chester est une histiocytose du groupe L survenant principalement chez l’adulte d’âge moyen. Sa physiopathologie a récemment été éclairée par la découverte de mutations activatrices des voies signalisation intracellulaire, principalement dans la voie des MAPK dans les histiocytes pathologiques des tissus atteints. Ces découverts ont permis l’avènement de nouvelles thérapies ciblées, avec une efficacité notable. De nombreuses inconnues sur la pathogénèse de la maladie demeurent, notamment concernant le phénotype immunitaire et clinique. Dans une première partie, nous montrons que la maladie d’Erdheim-Chester est fréquemment associée aux néoplasmes myéloïdes, avec de nombreuses mutations additionnelles, ce qui témoigne d’une physiopathologie commune entre les deux pathologies. Dans une deuxième partie, nous avons mis en évidence un profil monocytaire particulier, avec une augmentation des proportions de monocytes classiques et une diminution des proportions de monocytes non-classiques, ce qui rappelle le profil monocytaire retrouvé dans la leucémie myélo-monocytaire chronique, témoignant de l’association non-fortuite des deux maladies. Nous avons également mis en évidence que les lymphocytes Th17 circulants étaient significativement augmentés et les lymphocytes T régulateurs circulants diminués. Troisièmement, nous avons mis en place un modèle murin reproduisant pour la première fois une manifestation clinique typique de la maladie, à savoir l’ostéosclérose des os longs. Nous formulons également l’hypothèse que, comme dans les néoplasmes myéloïdes, l’ostéosclérose observée est le résultat d’une dérégulation des protéines impliquées dans le remodelage osseux : ostéoprotégérine et RANK-L.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
La maladie d’Erdheim-Chester au-delà de la voie des MAPKinases : association aux néoplasmes myéloïdes et mutations additionnelles, profil des monocytes et de polarisation lymphocytaire T, interaction avec l’ostéogénèse
La maladie d’Erdheim-Chester est une histiocytose du groupe L survenant principalement chez l’adulte d’âge moyen. Sa physiopathologie a récemment été éclairée par la découverte de mutations activatrices des voies signalisation intracellulaire, principalement dans la voie des MAPK dans les histiocytes pathologiques des tissus atteints. Ces découverts ont permis l’avènement de nouvelles thérapies ciblées, avec une efficacité notable. De nombreuses inconnues sur la pathogénèse de la maladie demeurent, notamment concernant le phénotype immunitaire et clinique. Dans une première partie, nous montrons que la maladie d’Erdheim-Chester est fréquemment associée aux néoplasmes myéloïdes, avec de nombreuses mutations additionnelles, ce qui témoigne d’une physiopathologie commune entre les deux pathologies. Dans une deuxième partie, nous avons mis en évidence un profil monocytaire particulier, avec une augmentation des proportions de monocytes classiques et une diminution des proportions de monocytes non-classiques, ce qui rappelle le profil monocytaire retrouvé dans la leucémie myélo-monocytaire chronique, témoignant de l’association non-fortuite des deux maladies. Nous avons également mis en évidence que les lymphocytes Th17 circulants étaient significativement augmentés et les lymphocytes T régulateurs circulants diminués. Troisièmement, nous avons mis en place un modèle murin reproduisant pour la première fois une manifestation clinique typique de la maladie, à savoir l’ostéosclérose des os longs. Nous formulons également l’hypothèse que, comme dans les néoplasmes myéloïdes, l’ostéosclérose observée est le résultat d’une dérégulation des protéines impliquées dans le remodelage osseux : ostéoprotégérine et RANK-L.
- 5 February 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (4) , 876-879
Diagnostic Yield and Risks Associated With Retroperitoneal Biopsy in Erdheim‐Chester Disease
- 5 February 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (4) , 876-879
Diagnostic Yield and Risks Associated With Retroperitoneal Biopsy in Erdheim‐Chester Disease
- Open Access
Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection
Objective: This study aimed to evaluate the prevalence of hyposplenism in patients with systemic lupus erythematosus (SLE) and its association with an increased risk of infection. Methods: This single-centre study included patients with SLE who underwent a systematic evaluation for Howell-Jolly bodies (HJB) on peripheral blood smear, a marker of hyposplenism. Patients exhibiting HJB were classified as having hyposplenism (cases), whereas those without such inclusions were considered to have normal splenic function (controls). We collected radiological data to assess spleen morphology. The prevalence of infections and thrombosis was recorded. Results: In a tertiary care cohort of 245 patients, 23 (9.4%) demonstrated HJB on peripheral smear, after exclusion of those with a history of splenectomy or intrinsic haemolytic anaemia. In multivariable analysis, three factors were independently associated with hyposplenism: paediatric-onset SLE (OR 5.2, 95% CI 1.3 to 21.2, p=0.02), antiphospholipid syndrome (OR 6.8, 95% CI 2.2 to 20.8, p=0.001) and history of constitutional symptoms of SLE (OR 3.9, 95% CI 1.2 to 12.4, p=0.02). Patients with HJB had a higher risk of infection-related hospitalisation (OR 7.3, 95% CI 2.4 to 21.8, p<0.001), particularly pneumococcal infections (5/23 cases (21.7%) vs 1/222 controls (0.5%), p<0.001), but no increased risk of thrombosis (OR 1.6, 95% CI 0.3 to 7.8, p=0.57). Hyposplenism was associated with splenic hypoplasia identified on abdominal CT scan (6/23 assessed cases (26%) vs 0/166 assessed controls (0%), p<0.001), but not with splenic calcifications. Hyposplenism was also associated with eosinophilia, neutrophilia, monocytosis and thrombocytosis. Conclusion: Hyposplenism was observed in 9.4% of patients with SLE in a tertiary care cohort and was significantly associated with an increased risk of infection and radiological splenic hypoplasia. These findings highlight the importance of preventive measures for impaired splenic function, including patient and physician education, vaccination and infection surveillance in this population.
Open AccessHyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection
Objective: This study aimed to evaluate the prevalence of hyposplenism in patients with systemic lupus erythematosus (SLE) and its association with an increased risk of infection. Methods: This single-centre study included patients with SLE who underwent a systematic evaluation for Howell-Jolly bodies (HJB) on peripheral blood smear, a marker of hyposplenism. Patients exhibiting HJB were classified as having hyposplenism (cases), whereas those without such inclusions were considered to have normal splenic function (controls). We collected radiological data to assess spleen morphology. The prevalence of infections and thrombosis was recorded. Results: In a tertiary care cohort of 245 patients, 23 (9.4%) demonstrated HJB on peripheral smear, after exclusion of those with a history of splenectomy or intrinsic haemolytic anaemia. In multivariable analysis, three factors were independently associated with hyposplenism: paediatric-onset SLE (OR 5.2, 95% CI 1.3 to 21.2, p=0.02), antiphospholipid syndrome (OR 6.8, 95% CI 2.2 to 20.8, p=0.001) and history of constitutional symptoms of SLE (OR 3.9, 95% CI 1.2 to 12.4, p=0.02). Patients with HJB had a higher risk of infection-related hospitalisation (OR 7.3, 95% CI 2.4 to 21.8, p<0.001), particularly pneumococcal infections (5/23 cases (21.7%) vs 1/222 controls (0.5%), p<0.001), but no increased risk of thrombosis (OR 1.6, 95% CI 0.3 to 7.8, p=0.57). Hyposplenism was associated with splenic hypoplasia identified on abdominal CT scan (6/23 assessed cases (26%) vs 0/166 assessed controls (0%), p<0.001), but not with splenic calcifications. Hyposplenism was also associated with eosinophilia, neutrophilia, monocytosis and thrombocytosis. Conclusion: Hyposplenism was observed in 9.4% of patients with SLE in a tertiary care cohort and was significantly associated with an increased risk of infection and radiological splenic hypoplasia. These findings highlight the importance of preventive measures for impaired splenic function, including patient and physician education, vaccination and infection surveillance in this population.